Follow The Filings

SKYE Skye Bioscience

Skye Bioscience earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS — -0.27 —
Rev — — —

Insider trades

Open-market buys and sales by SKYE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SKYE insider trades
  • None no insider bought on the open market
  • $889K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Andrew J. Schwab Director
    Sale
    $240K 148,079 shares at $1.62 100% of stake
    Traded Sep 22–23 Filed Sep 24
    ↗
  2. Andrew J. Schwab Director
    Sale
    $65K 33,892 shares at $1.91 86% of stake
    Traded Sep 16 Filed Sep 18
    ↗
  3. Andrew J. Schwab Director
    Sale
    $140K 375,840 shares at $0.3700 4.6% of stake
    Traded Aug 18–20 Filed Aug 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.02,5.02,8.01 Filing Doc
DEFA14A Filing Doc
8-K 1.01,3.02,9.01 Filing Doc
DEFA14A Filing Doc
8-K/A 3.03 Filing Doc
DEFA14A Filing Doc
8-K 3.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,3.02,3.03,5.01,5.02,5.03,7.01,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 8.01 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
8-K 3.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K/A 5.02 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 3.01 Filing Doc
10-K Filing Doc
8-K 2.02 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.